文献速递浆细胞疾病

多发性骨髓瘤与意义未明单克隆丙种球蛋白血症对同一抗骨髓瘤治疗的反应比较:一项回顾性队列研究

Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
PubMed 文献 · Lancet Haematol · 2017-11-13

该回顾性队列研究从英国三项临床试验的6399例新诊断多发性骨髓瘤患者中识别出44例双克隆丙种球蛋白病多发性骨髓瘤患者,比较同一抗骨髓瘤治疗对骨髓瘤克隆(M1)与MGUS克隆(M2)的疗效差异。结果显示M1克隆缓解率41例(93%)高于M2克隆28例(64%),p=0.0010;接受非强化治疗的17例患者中M1缓解16例(94%)高于M2的10例(59%),p=0.031。

要点

  • 44例双克隆丙种球蛋白病多发性骨髓瘤患者中,M1克隆缓解41例(93%)vs M2克隆缓解28例(64%),p=0.0010。
  • 接受非强化治疗的17例中,M1克隆缓解16例(94%)vs M2克隆缓解10例(59%),p=0.031。
  • 44例中有30例(68%)患者体内M1与M2克隆的缓解程度不同;1例M2进展为骨髓瘤后死亡。

核心结论

  • 在双克隆丙种球蛋白病多发性骨髓瘤患者中,抗骨髓瘤治疗对骨髓瘤浆细胞克隆的缓解深度大于对MGUS浆细胞克隆的缓解深度。
  • 部分MGUS克隆可达完全缓解,但许多MGUS克隆无缓解,提示仅部分MGUS浆细胞克隆具备使骨髓瘤浆细胞对治疗敏感的 underlying 特征。
  • 作者提出未来研究可以双克隆丙种球蛋白病多发性骨髓瘤为研究模型,寻找影响MGUS浆细胞克隆对抗骨髓瘤治疗反应的遗传与表观遗传改变。

研究设计与样本

  • 回顾性队列研究,通过中心实验室分析2004年7月7日至2015年6月2日期间入组英国三项临床试验(Myeloma IX、Myeloma XI和TEAMM)的6399例新诊断多发性骨髓瘤患者,识别双克隆丙种球蛋白病多发性骨髓瘤患者。
  • 除三项试验的入组标准外,本研究要求入组时免疫固定电泳存在两种不同的M蛋白。
  • 共识别44例具有IgG或IgA型MGUS克隆的双克隆丙种球蛋白病多发性骨髓瘤患者并进行纵向监测,按意向治疗分析。
  • 主要终点为抗骨髓瘤治疗对MGUS克隆(定义为M2)与骨髓瘤克隆(M1)的缓解差异,包括总体、患者内及不同治疗类型间,采用国际治疗反应标准以χ2分析评估。

主要发现

  • 44例患者中,M1克隆缓解41例(93%)vs M2克隆缓解28例(64%),p=0.0010。
  • 接受强化治疗的20例患者中,M1克隆缓解19例(95%)vs M2克隆缓解15例(75%),p=0.13。
  • 接受非强化治疗的17例患者中,M1克隆缓解16例(94%)vs M2克隆缓解10例(59%),p=0.031。
  • 44例患者中30例(68%)个体内M1与M2克隆的缓解程度不同;1例患者M2进展为骨髓瘤并随后死亡。

关键数值与推荐

  • M1克隆缓解定义包括完全缓解、非常好的部分缓解、部分缓解或微小缓解。
  • 强化治疗组20例中M1克隆缓解19例(95%)vs M2克隆缓解15例(75%),p=0.13,未达统计学显著。
  • 非强化治疗组17例中M1克隆缓解16例(94%)vs M2克隆缓解10例(59%),p=0.031。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiple myeloma is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS), which is usually only treated by a form of anti-multiple myeloma therapy if it is causing substantial disease through deposition of secreted M proteins. However, studies comparing how MGUS and multiple myeloma plasma cell clones respond to these therapies are scarce. Biclonal gammopathy multiple myeloma is characterised by the coexistence of an active multiple myeloma clone and a benign MGUS clone, and thus provides a unique model to assess the responses of separate clones to the same anti-multiple myeloma therapy, in the same patient, at the same time. We aimed to identify how MGUS and multiple myeloma plasma cell clones responded to anti-multiple myeloma therapy in patients newly diagnosed with biclonal gammopathy multiple myeloma. METHODS: In this retrospective cohort study, we identified patients with biclonal gammopathy multiple myeloma by central laboratory analysis of 6399 newly diagnosed patients with multiple myeloma enrolled in three UK clinical trials (Myeloma IX, Myeloma XI, and TEAMM) between July 7, 2004, and June 2, 2015. In addition to the inclusion criteria of these trials, our study necessitated at trial entry the presence of two distinct M proteins in immunofixation electrophoresis. The primary endpoint was difference in response achieved with anti-multiple myeloma therapy on MGUS (which we defined as M2) and multiple myeloma (M1) clones-overall, within patients, and between therapy types-with international therapy response criteria assessed with χ2 analyses. We analysed by intention to treat. FINDINGS: 44 patients with biclonal gammopathy multiple myeloma with IgG or IgA MGUS clones were subsequently identified from the three trials and then longitudinally monitored. 41 (93%) of M1 clones had a response to therapy (either complete response, very good partial response, partial response, or minor response) compared with only 28 (64%) of M2 clones (p=0·0010). For the 20 patients who received intensive therapy, there was no difference between the proportion of responding clones in M1 (19 [95%]) and M2 (15 [75%], p=0·13). However, for the 17 patients who received non-intensive therapy, 16 (94%) of M1 clones had a response compared with ten [59%] of M2 clones (p=0·031). When examining clones within the same patient, 30 (68%) of 44 individual patients had different levels of responses within the M1 and M2 clones. One patient exhibited M2 progression to myeloma and subsequently died. INTERPRETATION: These results show that, in patients with biclonal gammopathy multiple myeloma, anti-multiple myeloma therapies exert a greater depth of response against multiple myeloma plasma cell clones than MGUS plasma cell clones. Although some MGUS clones exhibited a complete response, many did not respond, which suggests that the underlying features that render multiple myeloma plasma cells susceptible to therapy are present in only some MGUS plasma cell clones. To determine MGUS clone susceptibly to therapy, future studies might seek to identify, with biclonal gammopathy multiple myeloma as an investigative model, the genetic and epigenetic alterations that affect whether MGUS plasma cell clones are responsive to anti-multiple myeloma therapy. FUNDING: National Institute of Health Research, Medical Research Council, and Cancer Research UK.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Campbell JP, Heaney JLJ, Pandya S, et al. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. Lancet Haematol. 2017. PMID: 29146225. doi:10.1016/S2352-3026(17)30209-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。